The latest news from academia, regulators
research labs and other things of interest
Posted: Oct 11, 2012
NanoGuardian's On-Dose NanoEncryption Brand Protection Technology Presented at AAPS
(Nanowerk News) NanoGuardian™, a division of NanoInk®, Inc. that delivers on-dose
brand protection solutions to the pharmaceutical industry to fight counterfeiting and illegal diversion,
announced today that it will give a poster presentation at the American Association of Pharmaceutical
Scientists (AAPS) Annual Meeting and Exhibition, which is being held on October 14 – 18, at
McCormick Place in Chicago. The abstract, “Can Nanofabrication be used to Combat Counterfeit
Medicines by Applying On-dose Authentication Features without Disrupting the Integrity of the
Medicine?” will be presented on Monday, October 15, from 1:30 to 4:30 p.m. in Hall F by Bjoern
Rosner, director of research and development, brand protection for NanoGuardian.
“Counterfeit medicines have become such a problem that pharmaceutical manufacturers are evaluating
how to best ensure the integrity of their medicines for patients early in the drug development process,”
said Dean Hart, chief commercial officer of NanoGuardian. “The AAPS poster presentation will
demonstrate that NanoGuardian’s NanoEncryption technology can be used to incorporate highly
sophisticated nanoscale, authentication, and tracing features directly on film-coated tablets, gelatin
capsules, and vial caps without affecting the dissolution or stability of the medication – important
considerations in the development and commercialization of a new medication.”
NanoGuardian’s NanoEncryption technology is the only on-dose, multi-layered, brand protection
solution that enables pharmaceutical manufacturers to authenticate and trace every single dose, from
plant to patient. NanoGuardian’s Closed-Loop Protection Program combines the on-dose
authentication and tracing benefits of NanoEncryption technology with a proactive supply chain
auditing program to identify counterfeit or illegally diverted pharmaceuticals entering the global supply
chain as early as possible.
NanoGuardian fights both counterfeiting and illegal diversion with a single technology that can be used
to protect capsules, tablets, vial caps, and single-use syringes providing a layered security of overt, covert,
and forensic features. The overt and covert security features allow dose-level authentication at any point
in the supply chain, while the forensic and nano-scale NanoCodes provide comprehensive tracing
information on each and every dose. NanoGuardian’s technology provides a strong benefit over other
on-dose technologies given that NanoGuardian’s security features are implemented with no additional
material or chemicals being added to the medication.
As evidence of the rapidly growing problem of counterfeit pharmaceuticals, a recent report from the U.S.
Customs and Border Protection and the U.S. Immigration and Customs Enforcement noted that the
domestic value of counterfeit pharmaceutical seizures in fiscal year 2011 rose by more than $11 million,
an increase of almost 200 percent. The implications for victims of counterfeit drugs are extremely
serious, often resulting in unexpected side effects, severe allergic reactions and even death.
AAPS provides a dynamic international forum for the exchange of knowledge among scientists to
enhance their contributions to health. It offers timely scientific programs, ongoing education,
opportunities for networking, and professional development. More information is available at:
NanoGuardian™, a division of NanoInk®, Inc., focuses exclusively on delivering brand protection solutions
to fight illegal diversion and counterfeiting. Anchored by NanoInk’s novel NanoEncryption™ technology,
NanoGuardian enables manufacturers to authenticate and trace the integrity of their products across the
supply chain. More information about NanoGuardian is available at www.nanoguardian.net.